Entera Bio Ltd. (ENTX) stock

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/30

$3.11−0.11 (-3.42%)

Close on Nov 13, 2026Market cap $538.47MP/E –Yield –

Entera Bio EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

For fiscal 2025 it was $0.25, up 0.0% from the year before. The highest annual figure on record is $2.49 in fiscal 2017.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$0.25	0.0%
FY2024	Dec 31, 2024	$0.25	-19.4%
FY2023	Dec 31, 2023	$0.31	-31.1%
FY2022	Dec 31, 2022	$0.45	-4.3%
FY2021	Dec 31, 2021	$0.47	-29.9%
FY2020	Dec 31, 2020	$0.67	-24.7%
FY2019	Dec 31, 2019	$0.89	-32.1%
FY2018	Dec 31, 2018	$1.31	-47.4%
FY2017	Dec 31, 2017	$2.49	+219.2%
FY2016	Dec 31, 2016	$0.78	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$0.11	+83.3%
Q2 FY2026	Jun 30, 2026	$0.14	+133.3%
Q1 FY2026	Mar 31, 2026	$0.07	-12.5%
Q3 FY2025	Sep 30, 2025	$0.07	+16.7%
Q2 FY2025	Jun 30, 2025	$0.06	+20.0%
Q1 FY2025	Mar 31, 2025	$0.06	-25.0%
Q3 FY2024	Sep 30, 2024	$0.08	0.0%
Q2 FY2024	Jun 30, 2024	$0.06	-25.0%
Q1 FY2024	Mar 31, 2024	$0.05	-54.5%
Q3 FY2023	Sep 30, 2023	$0.08	-27.3%
Q2 FY2023	Jun 30, 2023	$0.08	-38.5%
Q1 FY2023	Mar 31, 2023	$0.08	-27.3%
Q3 FY2022	Sep 30, 2022	$0.11	+10.0%
Q2 FY2022	Jun 30, 2022	$0.11	+10.0%
Q1 FY2022	Mar 31, 2022	$0.13	-23.5%
Q3 FY2021	Sep 30, 2021	$0.11	-8.3%
Q2 FY2021	Jun 30, 2021	$0.10	–
Q1 FY2021	Mar 31, 2021	$0.10	–
Q2 FY2020	Jun 30, 2020	$0.17	–
Q2 FY2019	Jun 30, 2019	$0.12	–